Plant Name: Erysimum canescens
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPR35; | |
| TSHR; | |
| CTDSP1; RECQL; APOBEC3G; TDP1; P4HB; PIK3CG; GLO1; ALOX12; HSD17B1; AKR1B1; HSD17B2; HSD17B10; HPGD; ALOX15; NOX4; ALDH1A1; USP2; TNKS; PARP1; TNKS2; POLB; APEX1; CD38; | |
| ACHE; GAA; | |
| PTPRS; | |
| TOP2A; | |
| INSR; DAPK1; SYK; FLT3; MYLK; GSK3B; | |
| CA2; CA12; CA7; CA4; | |
| AR; | |
| ESR2; | |
| ESRRA; | |
| ALOX5; TYR; MAOA; XDH; | |
| KDM4E; | |
| BACE1; | |
| MMP9; MMP12; MMP2; | |
| HIF1A; TP53; NFKB1; AHR; | |
| ABCG2; ABCC1; | |
| SLC22A12; | |
| L3MBTL1; SMN1;SMN2; | |
| THPO; LMNA; MCL1; MAPT; APP; TTR; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | APOBEC3G | DNA dC->dU-editing enzyme APOBEC-3G | Q9HC16 | CHEMBL1741217 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
| Enzyme_unclassified | PIK3CG | PI3-kinase p110-gamma subunit | P48736 | CHEMBL3267 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | MYLK | Myosin light chain kinase, smooth muscle | Q15746 | CHEMBL2428 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Phosphatase | PTPRS | Receptor-type tyrosine-protein phosphatase S | Q13332 | CHEMBL2396508 |
| SLC superfamily of solute carriers | SLC22A12 | Solute carrier family 22 member 12 | Q96S37 | CHEMBL6120 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.665E-10 | 1.727E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.318E-10 | 3.011E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, NOX4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 4.548E-10 | 3.809E-07 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, XDH |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.302E-08 | 5.786E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 4.661E-08 | 1.692E-05 | APOBEC3G, AR, CA12, CA2, CA4, CA7, ESR2, ESRRA, GLO1, L3MBTL1, MMP12, MMP2, MMP9, PARP1, TNKS, TP53 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 1.056E-07 | 3.149E-05 | ABCC1, ALOX12, ALOX15, ALOX5, SYK |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.483E-07 | 6.360E-05 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 3.301E-07 | 8.262E-05 | ALOX12, ALOX15, ALOX5, HPGD |
| MF | GO:0005488; binding | GO:0020037; heme binding | 5.391E-07 | 1.236E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, NOX4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.027E-06 | 2.237E-04 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.574E-06 | 3.296E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 2.718E-06 | 5.332E-04 | AR, CA2, CD38, CYP1A1, CYP1A2, ESRRA, FLT3, HPGD, HSD17B2, NFKB1, PARP1, TP53, TYR |
| BP | GO:0009987; cellular process | GO:1903376; regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway | 2.861E-06 | 5.473E-04 | HIF1A, MCL1, PARP1 |
| BP | GO:0008152; metabolic process | GO:0070988; demethylation | 2.865E-06 | 5.473E-04 | APEX1, CYP1A1, CYP1A2, CYP2C9, KDM4E |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 7.989E-06 | 1.318E-03 | CYP19A1, CYP1A1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.009E-05 | 1.600E-03 | CA12, CA2, CA4, CA7 |
| BP | GO:0009987; cellular process | GO:1901216; positive regulation of neuron death | 1.073E-05 | 1.657E-03 | GSK3B, MAPT, MCL1, PARP1, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.112E-05 | 1.705E-03 | CYP1A2, CYP2C19, CYP2C9 |
| CC | GO:0016020; membrane | GO:0016020; membrane | 1.202E-05 | 1.780E-03 | ABCC1, ABCG2, ACHE, ALOX12, ALOX15, ALOX5, APP, AR, BACE1, CA12, CA2, CA4, CD38, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, DAPK1, FLT3, GAA, GLO1, GPR35, GSK3B, HPGD, HSD17B10, HSD17B2, INSR, L3MBTL1, LMNA, MAOA, MAPT, MCL1, MMP2, NOX4, PARP1, PIK3CG, PTPRS, RECQL, SLC22A12, SYK, TDP1, TNKS, TNKS2, TSHR, TYR, USP2 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.409E-05 | 1.966E-03 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.409E-05 | 1.966E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.409E-05 | 1.966E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 1.441E-05 | 1.999E-03 | CYP19A1, HSD17B1, HSD17B2 |
| BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 1.662E-05 | 2.276E-03 | CYP1B1, DAPK1, GSK3B, HPGD, MAPT, MCL1, MMP9, NOX4, TOP2A, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0043410; positive regulation of MAPK cascade | 2.144E-05 | 2.795E-03 | ALOX15, APP, AR, FLT3, INSR, NOX4, PIK3CG, SYK, THPO, XDH |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.273E-05 | 2.942E-03 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 2.297E-05 | 2.942E-03 | INSR, MAPT, NOX4, TP53, XDH |
| BP | GO:0040007; growth | GO:0040008; regulation of growth | 3.252E-05 | 3.937E-03 | ALOX12, APP, AR, CD38, ESR2, HIF1A, INSR, MAPT, PTPRS, TNKS2, TP53 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 3.497E-05 | 4.184E-03 | AHR, AR, ESR2, ESRRA |
| BP | GO:0050896; response to stimulus | GO:0071320; cellular response to cAMP | 3.790E-05 | 4.510E-03 | APEX1, APP, NOX4, PIK3CG |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.216E-05 | 4.883E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 4.216E-05 | 4.883E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 4.216E-05 | 4.883E-03 | ALOX12, ALOX15 |
| BP | GO:0002376; immune system process | GO:0002682; regulation of immune system process | 4.364E-05 | 5.028E-03 | AHR, ALOX15, APOBEC3G, APP, CA2, CD38, CYP19A1, ESRRA, HIF1A, L3MBTL1, MMP12, MMP2, NFKB1, PTPRS, SYK, THPO, TP53 |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 5.146E-05 | 5.898E-03 | NOX4, PARP1, POLB, TP53 |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 5.527E-05 | 6.179E-03 | AKR1B1, APEX1, CYP1B1, MMP9, TP53 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 5.527E-05 | 6.179E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 6.559E-05 | 7.105E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 7.574E-05 | 8.021E-03 | HPGD, MMP2, MMP9 |
| BP | GO:0050896; response to stimulus | GO:0034097; response to cytokine | 7.693E-05 | 8.092E-03 | ALOX15, CD38, DAPK1, FLT3, GSK3B, HIF1A, MCL1, NFKB1, TP53 |
| BP | GO:0051179; localization | GO:0051222; positive regulation of protein transport | 8.069E-05 | 8.402E-03 | ACHE, APP, CD38, GSK3B, HIF1A, MMP12, PARP1, SYK, TP53 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 8.411E-05 | 8.402E-03 | TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 8.411E-05 | 8.402E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 8.411E-05 | 8.402E-03 | CYP1A2, CYP2C9 |
| MF | GO:0005488; binding | GO:0051425; PTB domain binding | 8.411E-05 | 8.402E-03 | APP, INSR |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 8.411E-05 | 8.402E-03 | ALDH1A1, AR |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 8.686E-05 | 8.563E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0097237; cellular response to toxic substance | 9.123E-05 | 8.909E-03 | AKR1B1, APEX1, CYP1B1, NFKB1, TP53 |
| BP | GO:0009987; cellular process | GO:0051129; negative regulation of cellular component organization | 9.623E-05 | 9.355E-03 | APP, AR, GSK3B, LMNA, MAPT, PARP1, PTPRS, TNKS, TNKS2, TOP2A |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 9.814E-05 | 9.460E-03 | AR, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
| MF | Unclassified; | GO:0140097; catalytic activity, acting on DNA | 1.006E-04 | 9.568E-03 | APEX1, PARP1, POLB, RECQL, TDP1, TOP2A |
| BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 1.029E-04 | 9.743E-03 | ALOX15, GSK3B, HIF1A, INSR, MAPT, MMP9, NOX4, TNKS, TNKS2, TP53 |
| MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 1.035E-04 | 9.755E-03 | AHR, HIF1A, MCL1, NFKB1, P4HB, TOP2A, TP53, TTR, TYR |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 5.665E-10 | 9.347E-08 | HSD17B1; ALOX5; INSR; HSD17B2; CYP1A1; CYP1B1; CYP19A1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.371E-07 | 1.237E-05 | MAOA; GAA; ALOX15; AKR1B1; ALOX12; CYP2C19; TYR; CYP19A1; HSD17B10; CYP2C9; HSD17B1; ALOX5; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; CD38; XDH |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 6.680E-08 | 5.511E-06 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP19A1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.717E-07 | 9.445E-06 | CYP2C9; APP; MAOA; ALOX5; ALOX15; ALOX12; CYP2C19 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.730E-06 | 4.759E-05 | AR; GSK3B; FLT3; DAPK1; MMP2; HIF1A; TP53; MMP9; NFKB1; PIK3CG |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.103E-06 | 7.313E-05 | CYP2C9; ALOX5; ALOX15; ALOX12; CYP2C19 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.224E-05 | 2.027E-04 | PARP1; LMNA; TP53; NFKB1; PIK3CG; MCL1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.844E-05 | 2.340E-04 | GSK3B; AR; TP53; NFKB1; PIK3CG |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.750E-07 | 1.237E-05 | CA12; CA2; CA4; CA7 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.351E-05 | 2.027E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.236E-05 | 2.027E-04 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.620E-06 | 7.466E-05 | CYP2C9; CYP1A2; ALOX15; CYP2C19 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.493E-05 | 2.053E-04 | DAPK1; MMP2; MMP9; TP53 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 9.558E-05 | 1.051E-03 | GSK3B; SYK; CD38; TP53; NFKB1; PIK3CG |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 9.345E-05 | 1.051E-03 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.052E-04 | 1.085E-03 | FLT3; TP53; HIF1A; PIK3CG |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 2.446E-04 | 1.754E-03 | GSK3B; SYK; INSR; TP53; NFKB1; PIK3CG; MCL1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.393E-04 | 1.155E-03 | GSK3B; NFKB1; ESR2; PIK3CG |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.470E-04 | 1.155E-03 | GSK3B; SYK; NFKB1; PIK3CG |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.180E-04 | 1.145E-03 | CYP2C9; MAOA; CYP1A2; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.470E-04 | 1.155E-03 | CYP2C9; CYP1A2; CYP1A1; CYP1B1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 3.732E-04 | 2.565E-03 | BACE1; APP; GSK3B; MAPT; HSD17B10 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 3.887E-04 | 2.565E-03 | INSR; TP53; NFKB1; PIK3CG |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 4.732E-04 | 3.003E-03 | MMP2; MMP9; ESR2; PIK3CG |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 8.803E-04 | 4.464E-03 | MMP2; TP53; HIF1A; MMP9; PIK3CG |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 7.537E-04 | 4.146E-03 | ABCC1; CYP1B1; TP53; MMP9; NFKB1; MCL1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 5.115E-04 | 3.126E-03 | HPGD; FLT3; TP53; MMP9; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 5.497E-04 | 3.240E-03 | INSR; HIF1A; NFKB1; PIK3CG |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 6.805E-04 | 3.872E-03 | GSK3B; INSR; NFKB1; PIK3CG |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 9.198E-04 | 4.464E-03 | POLB; SYK; TP53; NFKB1; PIK3CG |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 9.157E-04 | 4.464E-03 | GSK3B; TP53; HIF1A; PIK3CG |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 9.749E-04 | 4.468E-03 | GSK3B; TP53; NFKB1; PIK3CG |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 9.749E-04 | 4.468E-03 | ABCC1; TP53; NFKB1; PIK3CG |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.427E-03 | 6.036E-03 | GSK3B; TP53; NFKB1; PIK3CG |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.549E-03 | 6.233E-03 | GSK3B; TP53; NFKB1; PIK3CG |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.008E-03 | 7.704E-03 | TP53; MMP9; NFKB1; PIK3CG |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 2.269E-03 | 8.509E-03 | GSK3B; INSR; NFKB1; PIK3CG |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 2.528E-03 | 9.068E-03 | POLB; GSK3B; TP53; NFKB1; PIK3CG |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 9.068E-04 | 4.464E-03 | GSK3B; TP53; PIK3CG |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.126E-03 | 5.020E-03 | INSR; TSHR; PIK3CG |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.185E-03 | 5.146E-03 | FLT3; NFKB1; PIK3CG |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.810E-03 | 7.112E-03 | TP53; NFKB1; PIK3CG |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 6.020E-03 | 1.910E-02 | MMP2; NFKB1; PIK3CG |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.512E-03 | 6.233E-03 | GSK3B; TP53; PIK3CG |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.416E-03 | 8.859E-03 | TP53; NFKB1; PIK3CG |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 2.353E-04 | 1.754E-03 | POLB; PARP1; APEX1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 3.843E-03 | 1.321E-02 | TP53; NFKB1; PIK3CG |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 7.616E-03 | 2.285E-02 | MMP9; NFKB1; PIK3CG |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 6.527E-03 | 2.032E-02 | GSK3B; NFKB1; PIK3CG |
| hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 4.100E-03 | 1.381E-02 | THPO; FLT3; CD38 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 4.786E-03 | 1.579E-02 | SYK; PARP1; NFKB1 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 1.010E-02 | 2.825E-02 | SYK; PIK3CG; MYLK |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 9.226E-03 | 2.625E-02 | ALOX5; NFKB1; PIK3CG |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.249E-02 | 3.379E-02 | SYK; NFKB1; PIK3CG |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 9.226E-03 | 2.625E-02 | MMP2; MMP9; PIK3CG |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.575E-02 | 3.999E-02 | SYK; INSR; PIK3CG |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.434E-02 | 3.697E-02 | GSK3B; INSR; PIK3CG |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 2.011E-02 | 4.783E-02 | THPO; PIK3CG; MCL1 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 2.011E-02 | 4.783E-02 | CD38; PIK3CG; MYLK |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 2.029E-02 | 4.783E-02 | HIF1A; PIK3CG |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.782E-02 | 4.389E-02 | TP53; PIK3CG |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.723E-02 | 4.306E-02 | GSK3B; TP53 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.330E-02 | 3.540E-02 | INSR; PIK3CG |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.383E-02 | 3.623E-02 | MAOA; NFKB1 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 8.924E-03 | 2.625E-02 | INSR; PIK3CG |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.126E-02 | 3.096E-02 | ABCC1; ABCG2 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 5.350E-03 | 1.731E-02 | GAA; AKR1B1 |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 7.233E-03 | 2.210E-02 | MAOA; TYR |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 3.164E-03 | 1.111E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.305E-04 | 1.155E-03 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia | E79.0, M10 | SLC22A12 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; MMP12; MMP12 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; HIF1A; PIK3CG; PIK3CG |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; PIK3CG; FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| NA: NA | Enthesopathy | NA | PIK3CG |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; PIK3CG |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | SYK; HIF1A; PIK3CG; TP53; FLT3; MMP9; MMP2; TOP2A |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; SYK; HIF1A; PIK3CG; TP53; FLT3; FLT3; MMP9; NFKB1; APP; PARP1; MMP2; MCL1; GSK3B; ACHE; CD38 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; MMP12 |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; SYK; SYK; MMP12; ESRRA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; PIK3CG; ABCC1; ESRRA |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; MYLK |
| C00-D49: Neoplasms | Glioma | C71 | PIK3CG; APP |
| NA: NA | GIST | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; INSR; ACHE |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; MMP2 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; TYR; SYK; AKR1B1; ESRRA |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; INSR; CYP19A1; PIK3CG; FLT3; FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | PIK3CG; CYP2C9 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; PIK3CG; PIK3CG; NFKB1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; ESRRA |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK; PIK3CG; PIK3CG |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; SLC22A12; ABCC1; ABCC1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR |
| NA: NA | HIV infections | NA | AHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; ACHE |
| NA: NA | Angioedema | NA | PIK3CG |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | PIK3CG; PIK3CG |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
| C00-D49: Neoplasms | Diffuse large B-cell lymphoma | C83.3 | PIK3CG |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PIK3CG; PARP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ACHE |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| C00-D49: Neoplasms | Endometrial cancer | C54.1 | PIK3CG; PIK3CG |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | INSR; APP; MAOA; GSK3B; ACHE; ACHE; ACHE; MAPT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; SYK |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; GSK3B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; ESRRA |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; SYK; PIK3CG; MMP12 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA; ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | PARP1; MMP2 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | PIK3CG |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53; CD38 |
| NA: NA | Edema | NA | CA2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | APP |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP2 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| NA: NA | Male hypogonadism | NA | AR |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA |
| C00-D49: Neoplasms | Melanoma | C43 | TYR; PARP1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; MMP2; ESRRA |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; SYK |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP; ACHE |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | PIK3CG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; CD38 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; MMP9 |